| Code | CSB-RA011087MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Cixutumumab, targeting the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a transmembrane tyrosine kinase receptor that plays a critical role in cell growth, proliferation, differentiation, and survival through activation of downstream signaling pathways including PI3K/AKT and MAPK cascades. Aberrant IGF1R signaling has been implicated in the pathogenesis and progression of various malignancies, including sarcomas, breast cancer, lung cancer, and colorectal cancer, where it contributes to tumor cell survival, metastasis, and resistance to conventional therapies.
Cixutumumab is a fully humanizedized IgG1 monoclonal antibody that binds to IGF1R with high affinity, blocking ligand binding and inducing receptor downregulation. This biosimilar antibody provides researchers with a valuable tool for investigating IGF1R-mediated signaling mechanisms, exploring the role of IGF1R in cancer biology, and studying potential therapeutic interventions targeting this pathway. It is suitable for various in vitro and in vivo research applications examining IGF1R function and its contribution to disease processes.
There are currently no reviews for this product.